Anti-CD40 antibodies
US10174121B2 · kind B2 · utility
2Cited by
17References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 27, 2016 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | Apr 2, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70578
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.